Decreases in markers of T-cells/T-cell activation (CD4, IL-2RA), macrophages (CSF1, CD163), and DCs (CLEC10A, CD40) were observed in AD lesions after dupilumab therapy. The gene discussed is CD4; the disease is Alzheimer disease.